The Department of Health and Human Services (HHS) sent out an RFI. AMCP provided a response which aims to promote precision medicine through a reconsideration of the "14 Day Rule".
Letters, Statements & Analysis
AMCP communicates the importance of managed care pharmacy by collaborating with members to provide comments, analysis, and testimony to Congress and federal and state agencies on the impact of proposed regulations and laws on managed care pharmacy and patients.
On July 4, President Donald Trump signed H.R. 1, the One Big Beautiful Bill Act, into law.
H.R. 1 will result in less preventive care and more preventable emergency room visits, increasing costs for everyone across the health care system and threatening hospitals with closure, which will further reduce access to critical care for American patients.
In Kennedy v. Braidwood Management, Inc., the plaintiffs challenged the constitutionality of the USPSTF, arguing that USPSTF members should be considered “principal officers” under the Appointments Clause and, therefore, must be appointed by the President and confirmed by the Senate.
As CMS explores strategies to increase the adoption of digital health tools, AMCP urges CMS to support broader coverage of prescription digital therapeutics (PDTs) under Medicare and Medicaid. PDTs represent an emerging class of software-based treatments that deliver clinically validated therapeutic benefits, either independently or in combination with other interventions. These products can play a transformative role in improving access, especially for patients with behavioral health conditions or chronic diseases.
Following House passage of congressional Republican’s budget reconciliation package, the One Big, Beautiful Bill Act (H.R. 1), Senate Republicans took to their respective committees to provide edits and changes to the massive tax-cut, border security, energy reform, and health care package.
As CMS explores strategies to increase the adoption of digital health tools, AMCP urges CMS to support broader coverage of prescription digital therapeutics (PDTs) under Medicare and Medicaid. PDTs represent an emerging class of software-based treatments that deliver clinically validated therapeutic benefits, either independently or in combination with other interventions. These products can play a transformative role in improving access, especially for patients with behavioral health conditions or chronic diseases.
Yesterday, the Senate Health, Education, Labor, and Pensions (HELP) Committee released the text and a section-by-section summary of its portion of the reconciliation bill. The package focuses largely on higher education, targeting financial assistance programs that Republicans allege inflate tuition costs at colleges and universities. While the committee adjusted certain policies in the One Big, Beautiful Bill Act (H.R. 1), the House’s version of reconciliation that passed last month, the draft bill leaves two policies that AMCP is tracking untouched.
State legislatures across the country have introduced bills designed to regulate the use of artificial intelligence (AI) systems by health care entities.
Today, the Congressional Budget Office (CBO) released an updated cost estimate for the One Big, Beautiful Bill Act (H.R. 1). This cost estimate incorporates the amendments made to H.R. 1 in the hours before the House passed the legislation by a vote of 215-214-1.
Academy of Managed Care Pharmacy (AMCP) issued a statement from CEO Susan A. Cantrell, MHL, RPh, CAE, following passage of the budget reconciliation bill that includes large-scale changes to Medicaid, the Affordable Care Act (ACA), Grad PLUS loans, and other programs.
Under the budget resolution adopted on April 10, 2025, the House Energy & Commerce Committee (E&C) is required to submit changes in laws under its jurisdiction to reduce the deficit by at least $880 billion over the fiscal years (FY) 2025-2034.
